Search

Keywords: Chronic pelvic pain; Gabapentin; Longer-term benefits EN Chronic pelvic pain Gabapentin Longer-term benefits 321 325 5 02/24/22 20220301 NES 220301 Yi-Feng Ren and Xiu-Mei Fan contributed equally to this work as co-first authors. There are some reasons: (i) In the present analysis, the change in pain scores was calculated as pain score at 3 months or 6 months minus baseline pain scores. [Extracted from the article]

Introduction: Gabapentin has potential analgesic benefits in patients with neuropathic pain, such as post-herpetic neuralgia and diabetic peripheral neuropathy neuropathic pain. However, its efficacy in women with chronic pelvic pain (CPP) remains contradictory. In the present study, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to ascertain the efficacy of this treatment. Methods: We systematically reviewed RCTs published in PubMed, Embase, the Cochrane Library, Web of Science, and Google Scholar databases, up to July 2021. These articles compared gabapentin with placebo or any other active treatment for CPP in women, with 'the change in pain scores from the baseline during the first 3 and 6 months of treatment' taken as the primary outcome. We considered reductions equivalent to 1.0 cm for primary outcomes to be clinically important. Results: Four studies, comprising 469 participants, were included in our meta-analysis. Results revealed that the gabapentin group had significantly higher change in pain intensity scores from baseline to 3 months [weighted mean difference (WMD) − 0.61 cm; 95% confidence interval (CI) − 0.97 to − 0.25; I2 = 0%; p = 0.0009] and 6 months (WMD − 1.38 cm; 95% CI − 1.89 to − 0.88; I2 = 0%; p < 0.00001), relative to the control group. The difference of 6-month pooled result was more clinically important. Results from analysis of secondary outcomes showed that gabapentin had no beneficial efficacy during the first 3 months of treatment. Although gabapentin treatment was associated with a higher risk of dizziness and somnolence, no statistically significant differences were observed with regards to the total incidence of adverse events. Conclusions: Overall, gabapentin could be a potential treatment option for CPP in women. However, as a pilot study, further studies are needed to explore the longer-term benefits and definite safety of this therapy in the future. Registration Number: PROSPERO registration number CRD42021249421. [ABSTRACT FROM AUTHOR]